This trial is to provide access for patients who have completed a Novartis or former GSK-sponsored study and are judged by the investigator as benefiting from continued treatment.
1 Primary · 1 Secondary · Reporting Duration: Baseline up to approximately 10 years after the first subject's first visit, or will remain open until treatment becomes commercially available and reimbursed, or another access program becomes available, whichever comes first.
Experimental Treatment
100 Total Participants · 3 Treatment Groups
Primary Treatment: trametinib · No Placebo Group · Phase 4
Age 18 - 100 · All Participants · 2 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: